Trial reportNeurogastroenterology and motility2020
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.
Trial report in Neurogastroenterology and motility, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 123 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inflammation and Intestinal Microbiota Modulation in Inflammatory Bowel Diseases
Effetto Del Trattamento Con Acido Butirrico Sull'Anoressia Nervosa
Who cites it
123 citing papers in PubMed, 4 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- The Role of Microbiota and Fecal Transplantation in Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2026Pooled it
- Gut microbiota metabolites in the immunoregulation of enteritis: research progress.Frontiers in immunology · 2025Pooled it
- Therapeutic and Immunologic Effects of Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Prebiotics for induction and maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2024Pooled it
- Effect of curcumin on the gut microbiota of patients with ulcerative colitis, Crohn's disease and healthy participants.Scientific reports · 2026Trial
- Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis: Results From a Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Trial
- Possible Role of Butyric Acid in Long-Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation.Neurogastroenterology and motility · 2025Trial
- Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial.Journal of pediatric gastroenterology and nutrition · 2025Trial
- The efficacy of preemptive multimodal analgesia in elderly patients undergoing laparoscopic colorectal surgery: a randomized controlled trial.Scientific reports · 2024Trial
- Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial.Lipids in health and disease · 2024Trial
- Trial
- Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.Neurogastroenterology and motility · 2021Trial
- Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.Neurogastroenterology and motility · 2020Trial
- Fecal Microbiota Transplantation and Microbiota-Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions.Clinical pharmacology and therapeutics · 2026Review
- Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections.Clinical microbiology reviews · 2026Review
- Microbially derived glutathione from Eubacterium rectale alleviates oxidative stress and promotes intestinal epithelial recovery.Microbiome · 2026Article
- Possible Mechanisms Underlying the Effects of Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2026Article
- [Butyrate alleviatesNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Distinct Gut Microbial Signatures and Diminished Anti-Inflammatory Effect of Short-Chain Fatty Acids in Schizophrenia With Immune Activation.Schizophrenia bulletin · 2026Article
- Human Colitis-on-Chip Model Reveals Dual Roles of Butyrate in Epithelial and Macrophage Defense Against Candida albicans Tissue Invasion.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundButyrate has shown anti-inflammatory and regenerative properties, providing symptomatic relief when orally supplemented in patients suffering from various colonic diseases. We investigated the effect of a colonic-delivery formulation of butyrate on the fecal microbiota of patients with inflammatory bowel diseases (IBDs).
methodsIn this double-blind, placebo-controlled, pilot study, 49 IBD patients (n = 19 Crohn's disease, CD and n = 30 ulcerative colitis, UC) were randomized to oral administration of microencapsulated-sodium-butyrate (BLM) or placebo for 2 months, in addition to conventional therapy. Eighteen healthy volunteers (HVs) were recruited to provide a healthy microbiota model of the local people. Fecal microbiota from stool samples was assessed by 16S sequencing. Clinical disease activity and quality of life (QoL) were evaluated before and after treatment. KEY
resultsAt baseline, HVs showed a different microbiota composition compared with IBD patients. Sodium-butyrate altered the gut microbiota of IBD patients by increasing bacteria able to produce SCFA in UC patients (Lachnospiraceae spp.) and the butyrogenic colonic bacteria in CD patients (Butyricicoccus). In UC patients, QoL was positively affected by treatment. CONCLUSIONS AND INFERENCES: Sodium-butyrate supplementation increases the growth of bacteria able to produce SCFA with potentially anti-inflammatory action. The clinical impact of this finding requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.